Influenza A Market: Epidemiology, Therapies, Companies, DelveInsight | Cidara Therapeutics, SAb Biotherapeutics, FluGen, Moderna, Vir Biotechnology, Vaxart

Posted on
by

Influenza A Market: Epidemiology, Therapies, Companies, DelveInsight | Cidara Therapeutics, SAb Biotherapeutics, FluGen, Moderna, Vir Biotechnology, Vaxart
Influenza A Market
The influenza A market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM influenza A market size from 2020 to 2034. The report also covers current influenza A treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market’s potential.

 

Influenza A therapies, such as XOFLUZA, RAPIVAB, FLUAD QUADRIVALENT, mRNA-1010, CD388, Flu Pandemic mRNA (GSK4382276A), CC-42344, and others, are expected to boost the Influenza A Market in the upcoming years.

 

DelveInsight has launched a new report on “Influenza A – Market Insights, Epidemiology, and Market Forecast-2034” that delivers an in-depth understanding of the Influenza A, historical and forecasted epidemiology as well as the Influenza A market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

Discover about the Influenza A market report @ https://www.delveinsight.com/report-store/influenza-a-infections-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

 

 

Some of the key facts of the Influenza A Market Report:

 

  • Leading companies in the Influenza A space include Roche, BioCryst Pharmaceuticals, Seqirus, Moderna, Cidara Therapeutics, GlaxoSmithKline, Cocrystal Pharma, and others.

  • The development pipeline for Influenza A features several promising mid- to late-stage candidates, including both drugs and vaccines, such as mRNA-1010, CD388, Flu Pandemic mRNA (GSK4382276A), CC-42344, and more.

  • In September 2024, the FDA approved AstraZeneca’s FluMist for self-administration, making it the first influenza vaccine that does not require a healthcare provider for administration. This nasal spray vaccine is suitable for individuals aged 2 to 49 years and is designed to improve convenience and accessibility for seasonal flu prevention.

  • In March 2024, the FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) recommended the composition of influenza vaccines for the 2024–2025 U.S. season. These recommendations rely on global surveillance data to ensure the vaccines target the most prevalent strains effectively.

  • The vaccinated population for Influenza A is segmented by age, including children (0–4 and 5–12 years), adolescents (13–17 years), adults (18–49, 50–64, and 65+ years), and pregnant women. In 2024, vaccination coverage was highest among adults aged 18–49 and lowest among pregnant women. Despite vaccination efforts, the estimated vaccine failure rate in the U.S. was approximately 70% in 2024.

  • In Japan, data from the Ministry of Health, Labour and Welfare indicated that the average number of Influenza A cases per medical institution in 2024 reached 64.39, surpassing the previous high of 57.09 recorded in January 2019. In Europe, the European Respiratory Virus Surveillance Summary (ERVISS, 2025) reported that the H1N1 pdm09 subtype accounted for the majority (57%–93%) of circulating Influenza A cases in 2024.

  • The emerging pipeline indicates improved treatment prospects for Influenza A, with advancements in early diagnosis and increased public awareness playing a critical role in enhancing outcomes.

  • Promising Influenza A therapies include XOFLUZA, RAPIVAB, FLUAD QUADRIVALENT, mRNA-1010, CD388, Flu Pandemic mRNA (GSK4382276A), CC-42344, and others.

 

Influenza A Overview

 

Influenza A viruses are categorized into subtypes based on two surface proteins: hemagglutinin (H) and neuraminidase (N). There are 18 H types and 11 N types identified, resulting in over 130 known combinations, most of which are found in wild birds. The currently circulating H1N1 strain originated from the 2009 pandemic and has since undergone genetic and antigenic evolution. Occasionally, a significant change called antigenic shift can occur, producing new subtypes that may trigger global pandemics due to widespread lack of immunity.

 

Symptoms of Influenza A can range from mild—such as fever, cough, fatigue, and sore throat—to severe conditions including pneumonia, sepsis, and breathing difficulties. Older adults and individuals with preexisting health conditions are at higher risk of serious complications.

 

Influenza A Market Outlook

 

Influenza A vaccines, updated annually based on global surveillance, play a vital role in preventing infection and reducing the severity of illness. Key vaccines, such as FLUZONE (inactivated) and FluMist (live attenuated), help stimulate protective antibodies, particularly benefiting high-risk populations like the elderly and individuals with chronic health conditions.

 

Alongside vaccines, antiviral medications such as TAMIFLU, RELENZA, RAPIVAB, and XOFLUZA are important for treating infections. When administered early, they can shorten the duration of illness by about a day and reduce the risk of complications, including pneumonia, especially in vulnerable patients.

 

Despite progress in vaccination and treatment, Influenza A remains a significant challenge due to its ongoing mutations through antigenic drift and shift. Continued efforts are required to address remaining gaps and improve understanding of the disease.

 

Discover how the Influenza A market is rising in the coming years @ https://www.delveinsight.com/sample-request/influenza-a-infections-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

 

Influenza A Marketed Drugs

 

  • XOFLUZA (baloxavir marboxil): Roche and Shionogi

  • RAPIVAB (peramivir): BioCryst Pharmaceuticals

 

Influenza A Emerging Drugs

  • CC-42344: Cocrystal Pharma

  • CD388: Cidara Therapeutics

 

Scope of the Influenza A Market Report

  • Study Period: 2020-2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Influenza A Companies: Cidara Therapeutics, SAb Biotherapeutics, FluGen, Moderna, Vir Biotechnology, Vaxart, and others

  • Key Influenza A Therapies: XOFLUZA, RAPIVAB, FLUAD QUADRIVALENT, mRNA-1010, CD388, Flu Pandemic mRNA (GSK4382276A), CC-42344, and others

  • Influenza A Therapeutic Assessment: Influenza A current marketed and Influenza A emerging therapies

  • Influenza A Market Dynamics: Influenza A market drivers and Influenza A market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Influenza A Unmet Needs, KOL’s views, Analyst’s views, Influenza A Market Access and Reimbursement

 

To know what’s more in our Influenza A report, visit https://www.delveinsight.com/report-store/influenza-a-infections-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

 

 

Key benefits of the Influenza A Market Report:

  1. Influenza A market report covers a descriptive overview and comprehensive insight of the Influenza A Epidemiology and Influenza A market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).

  2. The Influenza A market report provides insights into the current and emerging therapies.

  3. The Influenza A market report provides a global historical and forecasted market covering drug outreach in 7MM.

  4. The Influenza A market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Influenza A market.

 

Got queries? Click here to know more about the Influenza A market Landscape

 

Table of Contents

 

1. Report Introduction

2. Executive Summary

3. SWOT analysis

4. Influenza A Patient Share (%) Overview at a Glance

5. Influenza A Market Overview at a Glance

6. Influenza A Disease Background and Overview

7. Influenza A Epidemiology and Patient Population

8. Country-Specific Patient Population of Influenza A

9. Influenza A Current Treatment and Medical Practices

10. Unmet Needs

11. Influenza A Emerging Therapies

12. Influenza A Market Outlook

13. Country-Wise Influenza A Market Analysis (2020–2034)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. Influenza A Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

Click here to read more about Influenza A Market Outlook 2034

 

Related Reports:

Influenza A Pipeline Insights, DelveInsight

“Influenza A Pipeline Insight, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Influenza A market. A detailed picture of the Influenza A pipeline landscape is provided, which includes the disease overview and Influenza A treatment guidelines.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/